Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.


PARP Inhibitors for BRCA-Associated TNBC

October 5th 2017

HER2+ Breast Cancer: Neratinib Patient Selection

October 5th 2017

Breast Cancer: Dual HER2-Targeted Adjuvant Therapy

October 5th 2017

Adjuvant Therapy for ER+/HER2+ Breast Cancer

October 5th 2017

Post-Adjuvant Therapy for HER2+ Breast Cancer

October 5th 2017

Neoadjuvant PI3 Kinase Inhibitors for HR+ Breast Cancer

October 5th 2017

Fulvestrant in the Era of CDK4/6 Inhibitors for HR+ mBC

October 5th 2017

Abemaciclib With Hormone Therapy for HR+ mBC

October 5th 2017

Differences Among CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

Efficacy of CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

Biomarkers for CDK4/6 Inhibitors in HR+ mBC

October 5th 2017

CDK4/6 Inhibitors in HR+ Metastatic Breast Cancer

October 5th 2017

HR+ Breast Cancer: Updated Results From MONARCH Trials

October 2nd 2017

Abemaciclib's Value in Treating HR+ Breast Cancer

October 2nd 2017

HR+ Breast Cancer: Pooled Analysis From MONARCH 2 and 3

October 2nd 2017

HR+ Breast Cancer: Resistance to Primary Therapy

October 2nd 2017

Factors in Deciding Treatment for HR+ Breast Cancer

October 2nd 2017

Heterogeneity of Metastatic HR+ Breast Cancer

October 2nd 2017

Understanding Abemaciclib: A New CDK4/6 Inhibitor

October 2nd 2017

CDK4/6 Inhibitor Combinations for HR+ mBC

October 2nd 2017